Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 6/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.46 |
| ▸ | MMP13 | P45452 | 3/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MMP8 | P22894 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 2/20 | 0.42 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6727259 | 0.89 | MMP1 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6732559 | 0.89 | MMP13 (0.53) | MMP13MMP2MMP8ALDH1A1MMP1 | |
| SCHEMBL6727248 | 0.88 | MMP13 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6735747 | 0.82 | CHRNB2 (0.42) | MMP13MMP2MMP8MMP1 | |
| SCHEMBL6735054 | 0.81 | MMP13 (0.52) | MMP13MMP2MMP8ALDH1A1MMP1 | |
| SCHEMBL6730246 | 0.80 | HDAC1 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6976225 | 0.80 | MMP13 (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6977761 | 0.79 | HRH3 (0.39) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6727303 | 0.79 | MMP13 (0.62) | MMP13MMP2MMP8ALDH1A1MMP1 | |
| SCHEMBL28749443 | 0.77 | ALDH1A1 (0.47) | MMP13MMP2MMP8ALDH1A1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6680338-B2 | MATRIX METALLOPROTEINASE AND TUMOR NECROSIS FACTOR INHIBITORS; ANTICARCINOGENIC AGENTS; RHEUMATOID ARTHRITIS | DARWIN DISCOVERY LTD. (GB) | 2004-01-20 | — | — | US | claimed |
| US-20030236416-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 2003-12-25 | — | — | US | claimed |
| EP-1053233-B1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LTD (GB) | 2003-08-20 | — | — | EP | claimed |
| EP-1053233-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | Darwin Discovery Limited (GB) | 2000-11-22 | — | — | EP | claimed |
| WO-1999040080-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 1999-08-12 | — | — | WO | claimed |
| US-20040127717-A1 | Hydroxamic and carboxylic acid derivatives | MONTANA JOHN GARY (GB) | 2004-07-01 | — | — | US | disclosed |
| US-6680338-B2 | MATRIX METALLOPROTEINASE AND TUMOR NECROSIS FACTOR INHIBITORS; ANTICARCINOGENIC AGENTS; RHEUMATOID ARTHRITIS | DARWIN DISCOVERY LTD. (GB) | 2004-01-20 | — | — | US | disclosed |
| US-20030236416-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 2003-12-25 | — | — | US | disclosed |
| EP-1053233-B1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LTD (GB) | 2003-08-20 | — | — | EP | disclosed |
| EP-1053233-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | Darwin Discovery Limited (GB) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999040080-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236416-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | HCAR1, HCAR2, HCAR3 | HDAC3 22/4885HDAC4 242/4885HDAC1 60/4885 |
| US-20040127717-A1 | Hydroxamic and carboxylic acid derivatives | HCAR1, HCAR2, CBR1 | HDAC3 25/4885HDAC4 272/4885HDAC1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.